PT-141 10mg

Here's your full detailed PT-141 page rewrite, ready to paste:

PT-141 (Bremelanotide) — Full Product Page (Detailed Version)

Product Title:
PT-141 (Bremelanotide) — Synthetic Melanocortin Receptor Agonist Research Peptide (MC3R/MC4R)

Short Description:
A synthetic cyclic peptide within the melanocortin family, widely utilized in experimental pharmacology research as an agonist tool compound for probing melanocortin receptor activity, MC4R and MC1R signaling pathway dynamics, CNS-associated receptor signaling research, and inflammatory mediator regulation pathway investigation in controlled laboratory settings. ≥99% Purity, HPLC-Verified. Third-Party CoA Included. For in-vitro laboratory research use only.

Full Product Description:

Overview

PT-141 (Bremelanotide) is a synthetic peptide within the melanocortin family widely utilized in research environments to investigate melanocortin receptor (MCR) signaling mechanisms. In experimental pharmacology, PT-141 functions as an agonist tool compound for probing melanocortin receptor activity, with particular emphasis on MC4R and MC1R signaling pathway dynamics.

Closely related in structure to other synthetic melanocortin ligands including melanotan-derived peptides, PT-141 is applied in controlled laboratory systems to study ligand–receptor interactions, receptor selectivity parameters, and intracellular signaling cascade dynamics. These investigations are commonly conducted using a combination of cell-based assay systems and controlled preclinical animal research models to support mechanistic interpretation of experimental findings.

Biochemical Characteristics

• Peptide Sequence: Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)
• Molecular Formula: C₅₀H₆₈N₁₄O₁₀
• Molecular Weight: 1,025.182 g/mol
• PubChem CID: 9941379
• CAS Number: 189691-06-3

PT-141 is synthetically produced for use as a receptor-binding probe in melanocortin signaling research studies. Prior to experimental application, peptide identity and purity are verified through high-performance liquid chromatography (HPLC) and mass spectrometry (MS) to ensure suitability for receptor pharmacology assay systems.

Research Applications

Melanocortin Receptor Pharmacology & Selectivity Analysis
PT-141 is commonly employed as an agonist reference compound in melanocortin receptor pharmacology experiments. Researchers utilize it to quantify receptor activation profiles and compare signaling responses across melanocortin receptor subtypes under defined experimental conditions. Typical analytical endpoints include:

• Dose–response characterization and receptor activation profiling
• Receptor internalization and desensitization dynamics assessment
• Signaling bias evaluation using second-messenger and phosphorylation-based assay systems

CNS-Associated Signaling Research
In rodent and other controlled animal research models, melanocortin receptor activation is studied to map receptor-linked signaling within central nervous system (CNS) circuit dynamics. Experimental designs assess downstream molecular markers including:

• cAMP-responsive gene expression pathway dynamics
• ERK/MAPK phosphorylation signaling endpoint analysis
• Immediate-early gene activation pattern investigation
• Receptor subtype attribution via pharmacological or genetic control methodologies

Inflammation & Host-Response Pathway Research
MC1R-related signaling is examined in immune-relevant experimental systems to explore interactions between melanocortin pathway dynamics and inflammatory mediator regulation. In controlled preclinical inflammation and infection research models, melanocortin ligands have been utilized to measure:

• Cytokine profile endpoint dynamics
• Leukocyte signaling marker activity
• Tissue-level inflammatory response pathway endpoints

Pigmentation & Photobiology Research
In melanocyte-based research systems, melanocortin signaling is investigated for its role in pigmentation-associated transcriptional regulation and melanosome dynamics. MC1R-driven pathway activity is frequently evaluated in relation to:

• cAMP/PKA signaling pathway dynamics
• MAPK cross-talk signaling endpoint research
• Molecular response characterization under photobiological stressor conditions

Pathway & Mechanistic Context

Melanocortin receptors are members of the G protein–coupled receptor (GPCR) superfamily and predominantly signal through Gs-mediated pathways in controlled experimental systems, resulting in elevated intracellular cAMP levels and activation of PKA-dependent transcriptional programs.

In cellular assay systems, PT-141–induced signaling activity is commonly assessed through:

• cAMP accumulation pathway measurements
• CREB-mediated transcriptional activity endpoints
• Downstream phosphorylation event analysis including ERK/MAPK activation dynamics

Because melanocortin receptor subtypes can be co-expressed across different tissue types and experimental model systems, mechanistic studies typically rely on selective antagonists, receptor knockdown or knockout strategies, or controlled receptor expression systems to associate observed signaling outcomes with specific receptor populations under defined experimental conditions.

Preclinical Research Summary

Preclinical investigations involving melanocortin receptor agonists include studies utilizing rodent neurobehavioral and neuroendocrine research models to characterize MC4R-associated signaling networks. MC4R-deficient animal research models have been applied to examine molecular and signaling consequences of disrupted melanocortin pathway activity, supporting interpretation of receptor-specific experimental effects.

Additional preclinical research has explored melanocortin pathway involvement in neurobehavioral signaling dynamics and related molecular endpoints using controlled agonist-based study designs. In immune-focused controlled animal research models, melanocortin signaling has also been evaluated for its role in inflammatory mediator regulation and macrophage-associated pathway dynamics under defined experimental infection and inflammation research conditions.

All findings are derived exclusively from controlled preclinical research systems and do not represent clinical outcomes of any kind.

Form & Analytical Validation

PT-141 is supplied as a synthetic research peptide intended for controlled laboratory use. Standard quality control procedures include:

• Chromatographic Purity Analysis (HPLC) — purity profiling and lot consistency verification
• Mass-Based Identity Confirmation (MS) — molecular identity verification

Accompanying batch documentation is provided to support reproducibility across research-use-only (RUO) laboratory applications.

Purity & Quality

• ≥99% Purity — HPLC Verified
• Independently tested by accredited third-party laboratory
• Certificate of Analysis (CoA) available for every batch

Research Use Only (RUO) Notice

All products are furnished strictly for in-vitro laboratory research use only. "In-vitro" refers to studies conducted outside of a living organism in controlled laboratory conditions. These materials are not medicines or drugs and have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease or medical condition. Introduction into humans or animals is strictly prohibited. Not for human, medical, diagnostic, or veterinary use.

Here's your PT-141 storage page rewrite, ready to paste:

PT-141 (Bremelanotide) — Storage & Stability Guidelines

Page/Section Title:
PT-141 (Bremelanotide) — Storage, Stability & Lyophilization Information

Short Introduction:
All P1 Peptides PT-141 research compounds are manufactured using a lyophilization (freeze-drying) process to ensure maximum structural integrity and compound stability during transit and storage. The following guidelines are provided to support proper laboratory handling of this research-grade peptide material.

Manufacturing Process: Lyophilization

All PT-141 research compounds supplied by P1 Peptides are produced using lyophilization — also referred to as cryodesiccation — a specialized dehydration technique widely employed in the manufacture of research-grade synthetic peptide materials.

During this process, peptides are first frozen and then subjected to reduced pressure conditions, allowing frozen water to transition directly from solid to vapor phase — bypassing the liquid phase entirely. This yields a dry, porous white crystalline material — commonly referred to as a lyophilized peptide — that preserves full structural integrity of the compound throughout the handling and storage period.

In its lyophilized form, PT-141 research compounds remain stable during shipping for approximately 3 to 4 months without degradation under recommended conditions prior to reconstitution.

Reconstitution

When research protocols require reconstitution, PT-141 is typically prepared using bacteriostatic water under controlled laboratory conditions. Once reconstituted, the peptide solution should be stored under refrigeration to preserve compound integrity and structural stability. Reconstituted solutions maintain stability for up to 30 days when kept appropriately cold under refrigeration.

All reconstitution procedures should be carried out in accordance with standard laboratory protocols applicable to synthetic peptide research materials.

Recommended Storage Guidelines

The following storage parameters are recommended to maintain compound integrity throughout the research lifecycle:

Short-Term Storage — Unopened Lyophilized Vials

• Upon Delivery — Protect from heat and direct light exposure immediately upon receipt
• Short-Term Use (days to a few months) — Refrigeration below 4°C (39°F) is generally sufficient to maintain compound integrity
• Room Temperature Storage — Lyophilized PT-141 typically tolerates room-temperature storage for several weeks, making ambient storage acceptable for near-term laboratory research use prior to reconstitution

Long-Term Storage — Unopened Lyophilized Vials

• Extended Storage (several months to years) — Freezing is strongly recommended for long-term compound preservation
• Optimal Long-Term Preservation — Storage at ultra-low temperatures of approximately −80°C (−112°F) provides optimal protection and helps preserve peptide structural integrity over extended storage periods

Post-Reconstitution Storage

• Store reconstituted solutions under refrigeration below 4°C (39°F), away from direct light and heat sources
• Do not freeze reconstituted solutions
• Discard any unused reconstituted material after 30 days or upon observation of cloudiness, discoloration, or particulate matter

Additional Laboratory Guidance

For specific storage requirements applicable to this research compound, researchers should consult the Certificate of Analysis (CoA) provided with each batch, as well as applicable peer-reviewed literature and institutional laboratory protocols governing synthetic peptide handling and storage procedures.

Research Use Only (RUO) Notice

All products are furnished strictly for in-vitro laboratory research use only. These materials are not medicines or drugs and have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease or medical condition. Introduction into humans or animals is strictly prohibited. Not for human, medical, diagnostic, or veterinary use.